Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended			9 Months Ended
		Sep. 30, 2024	Sep. 01, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 28, 2024	Jun. 12, 2024	Apr. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]
Aggregate intrinsic value of stock options exercised					$ 4,700	$ 3,400
Weighted average grant date fair value of share-based awards granted					$ 89.09	$ 85.7
Weighted average grant date fair value of restricted stock units granted					$ 180.02
Total unrecognized compensation cost		$ 62,100			$ 62,100
Unrecognized compensation cost, weighted average remaining requisite service period					2 years 9 months 25 days
Number of unvested options and restricted stock units		2,300,804			2,300,804
Forfeited portion of grants	[1]				32,027
Share recalculated value								$ 136
Stock-based compensation expense		$ 23,055	$ 22,400	$ 6,373	$ 41,711	$ 19,110
Common stock, shares issued		56,026,725			56,026,725						55,766,078	55,557,698
FlexBiosys
Stockholders Equity Note Disclosure [Line Items]
Common stock, shares issued										2,770
Earnout consideration earned										20.00%
Avitide
Stockholders Equity Note Disclosure [Line Items]
Common stock, shares issued									28,638
Earnout consideration earned									50.00%
2018 Plan
Stockholders Equity Note Disclosure [Line Items]
Common stock shares reserved for Issuance													2,778,000
Incentive options, vesting period		1,487,289			1,487,289
Unvested Options
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period					5 years
Restricted Stock Units and Performance Stock Units
Stockholders Equity Note Disclosure [Line Items]
Aggregate intrinsic value of restricted stock units vested					$ 25,100	$ 32,300
Weighted average grant date fair value of restricted stock units granted					$ 180.02	$ 174.86
Restricted Stock Unit
Stockholders Equity Note Disclosure [Line Items]
Closing price of common stock							$ 148.82
2024 Grants
Stockholders Equity Note Disclosure [Line Items]
Forfeited portion of grants					32,776
Stock-based compensation expense		$ 17,400			$ 22,400

[1] Includes 13,057 options forfeited pursuant to the 2024 Award Amendment discussed above under “Chief Executive Officer Accounting Modifications”.